Pharma Tips

Risks of Hypoglycemic Drugs in Diabetics with CKD

By: Pharma Tips | Views: 1060 | Date: 21-Mar-2013

According to the World Diabetic Association (WBA), approximately 40% of adults with diabetes have some degree of chronic kidney disease (CKD). That's a lot of patients more than one might think.They should be getting an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker(ARB) for renoprotection, and blood pressure and lipids should be aggressively managed, but how does our approach to managing their antidiabetic therapy change?

Risks of Hypoglycemic Drugs in Diabetics with CKD

According to the World Diabetic Association (WBA), approximately 40% of adults with diabetes have some degree of chronic kidney disease (CKD). That's a lot of patients more than one might think.They should be getting an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker(ARB) for renoprotection, and blood pressure and lipids should be aggressively managed, but how does our approach to managing their antidiabetic therapy change?























We might consider taking a more aggressive approach to their glycemic control. In some clinical trial reports, tight glycemic control has been shown to be the primary determinant of decreased micro vascular complications. However, once we've decided how aggressively to manage glycemia, the choice of which antidiabetic to use and is especially important in these patients. Unfortunately, when the therapeutic strategy is to maximize glycemic control, the risk of hypoglycemia also increases - in both frequency and severity. Patients taking oral anti diabetics that are primarily eliminated by the kidneys are particularly susceptible. Furthermore, it should be noted that older patients are also at higher risk.

Dosing errors are common in CKD patients and can cause poor outcomes. Drugs cleared renally should be dose-adjusted based on creatinine clearance or estimated glomerular filtration rate (eGFR). Dose reductions, lengthening of the dosing interval, or both may be required.

As metformin is nearly 100% renally excreted, it is contraindicated in a number of patients: when serum creatinine is higher than 1.5 mg/dL in men or 1.4 mg/dL in women, in patients older than 80 years, or in patients with chronic heart failure. The primary concern here is that other hypoxic conditions (e.g., acute myocardial infarction, severe infection, respiratory disease, liver disease) may increase the risk of lactic acidosis. Because of this danger, and despite the fact that metformin is usually the recommended first-line treatment for type 2 diabetes, one should use caution when considering metformin in patients with renal impairment. Similarly, sulfonylureas should be used with care in diabetics with CKD. The clearance of both sulfonylureas and their metabolites is highly dependent on kidney function. As such, severe and sustained episodes of hypoglycemia due to sulfonylurea use have been described in dialysis patients.

Regardless of which antidiabetic agent is selected, HbA1c and kidney function should be regularly monitored and the antidiabetic regimen appropriately adjusted. As patients with type 2 diabetes tend to progress over time, most will require a combination of agents to achieve desired glycemic control. These combinations should be chosen carefully in patients with CKD.

Finally, awareness of and screening for renal impairment in diabetics is a necessary precursor to successful intervention. In these patients, CKD is underdiagnosed and under treated, and awareness of the disease is low among providers and patients alike. Early detection of disease via eGFR or urinary albumin excretion can lead to timely, evidence-based intervention and help prevent or delay progression of CKD. Check with the benefits in Improved kidney and cardiovascular outcomes, prevent emergencies, improving quality of life and lower associated costs.
Previous Page Next Page

People Searching On This Page:
  • best hypoglycemic drug in ckd
  • list of medicines banned in ckd
  • hypoglycemic agents in ckd

Related Pages


Walk in Interview for B.Pharm, M.Pharm, BSC, MSC to work at Hetero Drugs

Walk in Interview for B.Pharm, M.Pharm, BSC, MSC to work at Hetero Drugs

Jobs
Date:
01-Apr-2016  Views: 4821

HETERO, research based approved USFDA, TGA, EU, PMDA, KFDA and WHO global pharmaceutical company established in 1993, focused on development, manufact ...
After banning 300 drugs, Health Ministry examining 1,700 more products

After banning 300 drugs, Health Ministry examining 1,700 more products

News | FDA
Date:
17-Mar-2016  Views: 1717

NEW DELHI: The Health Ministry is examining as many as 1,700 more drug products to determine if they can be termed as safe, efficacious, and suitable ...
Govt bans more than 300 combination drugs sold illegally

Govt bans more than 300 combination drugs sold illegally

News | FDA
Date:
14-Mar-2016  Views: 1241

Government has banned the manufacture and sale of more than 300 combination medicines, including two widely used cough syrups, being sold without gove ...
B.Pharm/M.Pharm for Drugs Inspector under Directorate of Drugs control

B.Pharm/M.Pharm for Drugs Inspector under Directorate of Drugs control

Jobs | Drug Inspector
Date:
02-Mar-2016  Views: 22237

Online applications are invited from Indian Citizen and such other national as declared eligible by Government of India for recruitment to the 88 post ...
Drugs Inspector Job Vacancy  in Drugs Control Department of KPSC

Drugs Inspector Job Vacancy in Drugs Control Department of KPSC

Jobs | Drug Inspector
Date:
05-Jul-2012  Views: 24838

Vacancy for Drugs Inspector in Drugs Control department of KPSC - Freshers may apply ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

96  + 2 =     
Comments
People Searched About:
Best Hypoglycemic Drug In Ckd   |   List Of Medicines Banned In Ckd   |   Hypoglycemic Agents In Ckd   |  
Google : 143 times | Yahoo : 14 times | Bing : 33 times |